NASDAQ:BCAX Bicara Therapeutics (BCAX) Stock Price, News & Analysis $22.64 0.00 (0.00%) Closing price 09/18/2026 04:00 PM EasternExtended Trading$22.65 +0.01 (+0.04%) As of 09/18/2026 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOwnershipSEC FilingsShort Interest About Bicara Therapeutics Stock (NASDAQ:BCAX) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Bicara Therapeutics alerts:Sign Up Key Stats Today's Range$22.26▼$22.8650-Day Range$22.00▼$28.1552-Week Range$10.30▼$30.99Volume934,225 shsAverage Volume511,231 shsMarket Capitalization$1.50 billionP/E RatioN/ADividend YieldN/APrice Target$32.64Consensus RatingModerate Buy Company Overview Bicara Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing treatments for solid tumors. The company uses a proprietary bifunctional antibody platform designed to target tumor cells while modifying the surrounding tumor microenvironment, which may help improve the activity of cancer immunotherapies. Bicara’s lead product candidate is ficerafusp alfa, also known as BCA101. The investigational therapy is designed to block epidermal growth factor receptor (EGFR) signaling and inhibit transforming growth factor beta (TGF-β), two pathways associated with tumor growth and immune suppression. Bicara is evaluating ficerafusp alfa in combination with other therapies, including pembrolizumab, for patients with recurrent or metastatic head and neck squamous cell carcinoma and other solid tumors. Founded in 2020 and headquartered in Cambridge, Massachusetts, Bicara conducts clinical development activities primarily in the United States. The company became publicly traded on the Nasdaq under the symbol BCAX in 2024. Its pipeline and research programs are focused on expanding the use of bifunctional therapies across additional solid-tumor indications.AI Generated. May Contain Errors. Read More Bicara Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks35th Percentile Overall ScoreBCAX MarketRank™: Bicara Therapeutics scored higher than 35% of companies evaluated by MarketBeat, and ranked 695th out of 895 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.4 / 5Analyst RatingModerate Buy Consensus RatingBicara Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.80, and is based on 2 strong buy ratings, 9 buy ratings, 3 hold ratings, and 1 sell rating.Upside PotentialBicara Therapeutics has a consensus price target of $32.64, representing about 44.2% upside from its current price of $22.64.Amount of Analyst CoverageBicara Therapeutics has been the subject of 10 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Bicara Therapeutics' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Bicara Therapeutics are expected to decrease in the coming year, from ($3.51) to ($3.76) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Bicara Therapeutics is -7.30, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Bicara Therapeutics is -7.30, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioBicara Therapeutics has a P/B Ratio of 3.09. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Bicara Therapeutics' valuation and earnings. Short Interest0.0 / 5Short Interest LevelBearish Percentage of Shares Shorted19.01% of the float of Bicara Therapeutics has been sold short.Short Interest Ratio / Days to CoverBicara Therapeutics has a short interest ratio ("days to cover") of 22.08, which indicates bearish sentiment.Change versus previous monthShort interest in Bicara Therapeutics has recently increased by 3.65%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldBicara Therapeutics does not currently pay a dividend.Dividend GrowthBicara Therapeutics does not have a long track record of dividend growth. News and Social Media0.6 / 5News SentimentN/A News Coverage This WeekMarketBeat has tracked 1 news article for Bicara Therapeutics this week, compared to 5 articles on an average week.Search InterestOnly 1 people have searched for BCAX on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat Follows1 people have added Bicara Therapeutics to their MarketBeat watchlist in the last 30 days. Company Ownership1.2 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Bicara Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $3,479,986.00 in company stock.Percentage Held by Insiders13.80% of the stock of Bicara Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsBicara Therapeutics has minimal institutional ownership at this time.Read more about Bicara Therapeutics' insider trading history. Receive BCAX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Bicara Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. BCAX Stock News HeadlinesBicara Therapeutics Inc. (NASDAQ:BCAX) Receives Consensus Recommendation of "Moderate Buy" from AnalystsSeptember 17, 2026 | americanbankingnews.comInsider Selling: Bicara Therapeutics (NASDAQ:BCAX) CEO Sells 17,500 SharesSeptember 11, 2026 | insidertrades.comThe end may be near for these iconic stocksMarc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are triggering a historic wealth transfer already underway in 2026. Household names like Intuit (-57%), Boston Scientific (-49%), and Tractor Supply (-40%) are cratering, while lesser-known companies like Sandisk (+573%) and Rackspace (+444%) surge. Chaikin has identified specific stocks he believes investors should sell before they fall further - and the names may surprise you. He's also pinpointing a company tapped as Nvidia's self-driving partner and a potential AI megadeal that could split into three high-growth stocks. Stream his free presentation to get every buy and sell recommendation with no membership or credit card required. | Chaikin Analytics (Ad)Bicara Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)September 3, 2026 | globenewswire.comBicara Therapeutics Secures Boston Headquarters Through SubleaseAugust 25, 2026 | tipranks.comBicara Therapeutics’ Earnings Call Signals Pivotal ProgressAugust 23, 2026 | tipranks.comCan Bicara (BCAX) Commercialize Ficera? Breakthrough 3-Year Data Faces Execution Risk in C-Suite OverhaulAugust 19, 2026 | finance.yahoo.comBicara Therapeutics (BCAX) Q2 2026 Earnings Call TranscriptAugust 18, 2026 | finance.yahoo.comSee More Headlines BCAX Stock Analysis - Frequently Asked Questions How have BCAX shares performed this year? Bicara Therapeutics' stock was trading at $16.83 at the beginning of the year. Since then, BCAX stock has increased by 34.5% and is now trading at $22.64. How were Bicara Therapeutics' earnings last quarter? Bicara Therapeutics Inc. (NASDAQ:BCAX) posted its quarterly earnings results on Tuesday, August, 11th. The company reported ($0.82) earnings per share for the quarter, missing the consensus estimate of ($0.82) by $0.00. Read the conference call transcript. When did Bicara Therapeutics IPO? Bicara Therapeutics (BCAX) raised $298 million in an initial public offering (IPO) on Friday, September 13th 2024. The company issued 17,500,000 shares at $16.00-$18.00 per share. Who are Bicara Therapeutics' major shareholders? Bicara Therapeutics' top institutional investors include BlackRock Inc. (5.86%), Jupiter Topco LLC (4.79%), Palo Alto Investors LP (0.83%) and Walleye Capital LLC (0.54%). Insiders that own company stock include Ra Capital Management, LP, Claire Mazumdar, Ryan Cohlhepp, Ivan Hyep and David Raben. View institutional ownership trends. How do I buy shares of Bicara Therapeutics? Shares of BCAX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Last Earnings8/11/2026Today9/20/2026Next Earnings (Estimated)11/09/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (11m+) 1-Year History Sep 25 Dec 25 Mar 26 Jun 26 Sep 26 BCAX's financial health is in the Green zone, according to TradeSmith. BCAX has been in this zone for over 11 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:BCAX Previous SymbolNASDAQ:BCAX CIK2023658 Webwww.bicara.com Phone(617) 468-4219FaxN/AEmployees103Year Founded2020Price Target and Rating Average Price Target for Bicara Therapeutics$32.64 High Price Target$42.00 Low Price Target$20.00 Potential Upside/Downside+44.2%Consensus RatingModerate Buy Rating Score (0-4)2.80 Research Coverage15 Analysts Profitability EPS (Trailing Twelve Months)($3.10) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$137.95 million Net MarginsN/A Pretax MarginN/A Return on Equity-41.49% Return on Assets-38.59% Debt Debt-to-Equity RatioN/A Current Ratio11.59 Quick Ratio11.59 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$7.33 per share Price / Book3.09Miscellaneous Outstanding Shares66,170,000Free Float57,041,000Market Cap$1.50 billion OptionableN/A Beta-0.82 Social Links 10 Best Stocks to Own - Fall 2026Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Fall 2026, despite the economic uncertainty rattling markets right now. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free Report This page (NASDAQ:BCAX) was last updated on 9/21/2026 by MarketBeat.com Staff. From Our PartnersALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | SponsoredThey didn't warn anyone in 1971. This time someone is warning you.On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...Altimetry | SponsoredThe end may be near for these iconic stocksMarc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are ...Chaikin Analytics | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | SponsoredHere’s Why Trump Won’t End The Iran WarTrump has called an Iran deal close 38 times since the war began, yet the fighting keeps flaring back up. O...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Bicara Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Bicara Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
